Summary

The global market for aesthetic surgery and medicine, valued at $127.1 billion in 2023, is set to grow substantially, aiming to reach $332.1 billion. This growth trajectory has been driven by technological innovations in aesthetic devices, increasing non-invasive treatment options and growing acceptance of aesthetic procedures, particularly in the Asia-Pacific region, which has seen annual growth of over 10%.

The market remains dominated by the United States, which accounted for 45% of global sales by value in 2020, followed by Europe, Asia-Pacific and Latin America. Non-surgical procedures such as hyaluronic acid and botulinum toxin injections have surged. Socio-demographic factors such as an ageing population, changing beauty ideals influenced by social media and new consumer demographics, particularly men and young people, have all contributed to strong market growth from 2020 onwards.

Navigating the trends and growth dynamics of the French beauty market

In recent years, the French aesthetics market has experienced remarkable growth. Factors contributing to this growth include changing societal attitudes towards physical appearance, an ageing population that increasingly wishes to rejuvenate its appearance, and technological advances in non-invasive procedures. By 2021, the market has reached a value of around 10 to 15 billion euros, and this strong expansion is expected to maintain an annual growth rate of around 10 to 20% until at least 2024. In France, more than 300,000 cosmetic surgery operations and over 400,000 aesthetic medicine procedures were realized in 2022, testifying to the growing acceptance and search for aesthetic improvements among the French population.

Aesthetic surgery has seen an increase of around 10-15% in the space of a year, with the number of people undergoing procedures reaching around 1-2 million. This increase can be partly attributed to the aging of the population, with people aged 75 and over making up around 5-10% of the population by 2023, a figure that is expected to double by 2070. Demand for aesthetic services in France is strongly influenced by the fact that the boundary between aesthetics and medicine is blurring, as more and more people opt for less invasive procedures that promise temporary but immediate results. Among these procedures, hyaluronic acid and botulinum toxin injections are particularly important, as the country has seen a trend towards aesthetic medicine, which now accounts for around 50% of the market for aesthetic procedures.

Not to be overlooked is the influence of social media on younger generations, which has played a key role in changing ideals and perceptions of beauty. It has been observed that people aged between 18 and 25 are now more inclined to resort to cosmetic surgery than those aged between 50 and 60. This change is probably due to the desire to emulate the filtered perfection popularized by social media platforms.

In addition, advances in the production of medical and cosmetic surgery equipment have strengthened the structure of the market. France boasts a number of specialist manufacturers who contribute to a complex manufacturing chain in the cosmetic surgery and cosmeceutical segments. In general, production is led by international conglomerates, but some French companies have carved out a niche for themselves in injectables and cosmetics, maintaining production sites in the country. As the market evolves, so does the distribution framework, with a diverse range of distribution channels enjoying renewed activity.

Key players in the French aesthetic medicine and surgery market

The French market for aesthetic medicine and surgery is a dynamic, fast-growing sector, characterized by the presence of a number of established, leading players. Companies ranging from specialist equipment manufacturers to cosmetics giants and healthcare providers contribute to the bouquet of services and products that meet a wide range of consumer needs. Here's a look at the major players shaping the French market.

Allergan: A long-standing player and leader in the field of aesthetics, Allergan is known for its wide range of products, from injectables and breast implants to energy-based devices and cosmeceuticals. With a diversified product portfolio, Allergan has consolidated its position despite regulatory hurdles such as the withdrawal of its Biocell textured breast implants from the French market.
Eurosilicone (GC Aesthetics) and Laboratoires Sebbin: These two companies are renowned manufacturers of breast implants, supplying high-quality products to national and international markets. Thanks to the meticulous processes involved in creating these implants, they help to reinforce the confidence and reliability of aesthetic solutions.
Laboratoires Vivacy: A major player in the injectables market, Laboratoires Vivacy specializes in aesthetic and anti-aging products, including dermal fillers, in particular hyaluronic acid.
L'Oréal and its Cosmétique Active division: Building on its heritage in the beauty industry, L'Oréal's Cosmétique Active division, which includes Skinceuticals, Vichy and La Roche-Posay, is at the forefront of the cosmeceuticals segment. These brands combine cosmetic and therapeutic benefits to offer high-quality skincare products.
Deleo: Representing French prowess in medical technology, Deleo has marked its presence on the world stage with its innovative energy-based aesthetic devices. Specializing in cryolipolysis devices and high-power LED lamps, Deleo testifies to French industry's ability to innovate at the cutting edge of technology.
Merz and Galderma: Merz is known for its BoCouture product, while Galderma plays a crucial role with its botulinum toxin product Azzalure. Both companies contribute strongly to the botulinum toxin market in France, focusing on regulated aesthetic treatments.
Syneron-Candela and Lumenis: These international players occupy a strong position in the supply of energy-based devices, which include advanced lasers and body contouring systems.

the aesthetic medicine market - France

Get all the information you need
to understand this market

Buy the full study

Detailed content

Inforamtion

Number of pages : 30 pages
Format : Digital and PDF versions
Last update : 02/10/2023

Update Details

Summary and extracts

1 Market overview

1.1 Definitions and market overview

The aesthetic medicine and surgery market in France comprises several distinct segments[La Roche Posay; Le Figaro Santé] :

Aesthetic surgery

A speciality of plastic surgery, this technique of reshaping the body through surgical intervention corrects a morphological anomaly or the outward appearance of a patient's body. The results are radical .

Among the most common procedures are[Fashion4mec]:

Facial surgery: cervico-facial lift, rhinosplasty (nose), blepharoplasty (eyelids).
Breast surgery: breast augmentation, breast reduction, breast reconstruction, breast implant replacement.
Body surgery: abdominoplasty, liposuction, lipomodelling, intimate surgery.

Aesthetic medicine

This covers all non-surgical advice, care and treatment designed to improve a patient's aesthetic appearance. Described as "non-invasive", the vast majority of procedures involve injections under the skin, for example to reduce wrinkles. The result of a procedure is temporary and reversible. Aesthetic medical procedures must therefore be repeated to maintain their benefits .

The most common procedures include[CR] :

hyaluronic acid injection
botulinum toxin injections
tightening or lifting threads
cryolipolysis (cold fat removal)
laser hair removal
peeling (exfoliation/dermo-epidermal stimulation)
hair transplant

Cosmeceuticals

Halfway between cosmetics and drugs, cosmeceuticals contain active ingredients for specific dermatological treatments (wrinkles, dark circles, etc.). Cosmeceuticals are most frequently used to correct skin aging, although their efficacy has yet to be proven.

The first breast augmentations were performed in the 1950s/1960s, just as lasers were making their appearance in dermatology. Later, in the 80s, Dr Gérard Yllouz revolutionized cosmetic surgery by inventing liposuction. Finally, in the 90s and 2000s, aesthetic medicine emerged with the development of botox and hyaluronic acid.[Reau]

The global market for aesthetic surgery and medicine is booming, driven in particular by the dynamism of the Asian regions, which are currently the main focus of global demand. However, the market is still largely dominated by the United States and Brazil, and is valued at $127.1 billion in 2023, rising at a CAGR of14.7% from 2023 to 2030, to reach $332.1 billion. This growth is due in part to the boom in injectable substances, to the renewal of equipment and technologies required for operations, but also to the dual context of an ageing population and growing acceptance of cosmetic surgery. [GV]

The French market is also growing, thanks in particular to the growing popularity of aesthetic medicine methods, which straddle the line between medical treatment and simple cosmetic surgery.the French market is also growing, thanks in particular to the growing popularity of aesthetic medicine methods, which straddle the line between medical treatment and simple aesthetic procedures, to the detriment of in-clinic surgical procedures whose popularity has been affected by a number of scandals. The French aesthetics market will be worth 12 billion euros by 2021, with average annual growth of 15% from 2018 until at least 2024. [Clinique des Champs Elysées]

According to Le Figaro,more than 320,000 cosmetic surgery and 420,000 aesthetic medicine procedures were carried out in the country in 2022.As a result, the number of French people who have already had cosmetic surgery is estimated to have risen by 13% in one year, to 1.4 million.

Lastly, the legal framework plays a key role in regulating the market and authorizing certain practices. It therefore plays a decisive role in understanding market supply and major market dynamics [France Tv].

2 Demand analysis

3 Market structure

4 Offer analysis

5 Regulations

6 Positioning the players

6.1 Segmentation

Allergan plc
Galderma
Merz Pharmaceuticals
La Roche-Posay
Filorga Cosmétiques (Colgate Palmolive)
Lierac (Laboratoire Native)
Laboratoires Sebbin
Arion
Candela Medical
Deleo
Ipsen
Clinique des Champs Elysées
Lazeo
Maison Lutetia
Skincareagency

List of charts

The global aesthetic medicine market by value
Number of interventions by type
Beauty care market sales, APE code 96.02B
Population projections to 2070
Proportion of French population aged 65 and over
Feminization of the plastic surgery profession
Status of plastic surgeons
What type of cosmetic surgery have you had?
Personally, do you think you will resort to cosmetic surgery or medicine in the future?
The most common requests from men
Ranking of countries with the most foreign patients for cosmetic surgery
Breakdown of the most popular surgical procedures
Breakdown of main non-surgical procedures

Show more Hide

All our studies are available online in PDF format

Take a look at an example of our research on another market!

Example online Example in PDF

Do you have a question about this study? +44 238 097 0676

Latest news

Ipsen's commitment to the area of rare diseases - 29/02/2024

Performance and strategies of the biopharmaceutical company Ipsen in 2023: 1. **Increase in sales:** In 2023, Ipsen recorded an increase in global sales of 3.4% over the previous year. 2. **Operating margin:** The company recorded an operating margin of 26.1%, which shows an increase of 2% compared to 2022. 3. **Growth factors:** Growth was supported by the company's historical assets, new drugs, pipeline expansion, and accelerated investment in research and development, particularly benefited by recent acquisitions focused on the area of rare diseases. 4. **Entry into the rare disease area:** In 2023, Ipsen acquired Albireo, a leading developer of bile acid modulators for the treatment of pediatric and adult cholestatic liver disease, bringing odevixibat, the first approved treatment against progressive familial intrahepatic cholestasis (Pfic), to the market. 5. **Future Plans:** By 2024, Ipsen plans to launch four innovative therapies worldwide and expand its pipeline, supported by an external innovation strategy in its three core therapeutic areas. 6. **Rare disease commitment:** With new developments such as odevixibat and an evolving pipeline, Ipsen marks its official entry into the rare disease field, aiming to bring therapeutic innovations that can change the course of disease, with a focus on drugs with novel mechanisms of action.

Botox: botulinum toxin boosts pharma's bottom line - 02/08/2023

The United States accounts for half of the global botulinum toxin market.
Last year, Botox accounted for $5.2 billion in worldwide sales for AbbVie, with equal shares between aesthetics (+21% excluding currency effect) and therapeutics (+13%).
In the United States, Dysport (Ipsen) has only 5% of the therapeutic market, compared with 30% in France.
In aesthetics in the US, Ipsen has an estimated share of between 20% and 25%.
Of the French laboratory Ipsen's half-year sales of 1.5 billion euros (+7%), 319 million (+32%) come from botulinum toxin sold in therapeutics and, in some countries, in aesthetics.
Botox holds 40% to 50% of the therapeutic market in France, compared with 30% for Ipsen.

Aesthetic medicine: Blackstone bets on Lazeo to create a European heavyweight - 06/07/2023

The Lazeo network currently comprises 140 aesthetic medicine centers, making it the largest in Europe.
Lazeo plans to expand internationally with the help of investor Blackstone, which has acquired a 49.9% stake.
The Lazeo network currently has 800 employees and hopes to reach 500,000 customers by 2023, up from 300,000 in 2022.
A Lazeo center represents an average investment of 650,000 euros for the technical platform, and 250,000 euros for the lease and fittings.
Sales of 71 million (with a forecast of 100 million this year).
Currently, Lazeo has only 5 centers in Belgium and one in Germany
The aim is to have 400 centers of its own by 2027, mainly in France and Northern Europe.

Medicine, Allergan Aesthetics launches training center for healthcare professionals - 26/06/2023

Inauguration of Allergan Aesthetics' Center of Excellence in Italy, specifically in Rome. This center represents the first and only space completely dedicated to both theoretical and practical training of healthcare professionals. Its foundation is supported by the expertise of a multidisciplinary scientific committee composed of 21 nationally and internationally renowned experts. The main goal of the center is to offer high-quality training to healthcare professionals through 4 complementary curricula in order to ensure maximum satisfaction of their patients.

"The potential of dermocosmetics is immense", says L'Oréal - 11/05/2023

One in four people has a skin problem.
After the age of 60, it affects one in two.
L'Oréal's dermocosmetics division posted sales of 5 billion euros, with growth of 22%.
The dermocosmetics segment represents 8% of the global beauty market, compared with 5% a few years ago.
L'Oréal's growth last year was two and a half times faster than the market.
La Roche-Posay and CeraVe are brands with sales of over €1 billion.

Ipsen exceeds its targets, helped by its Botox competitor - 11/02/2023

Family-owned laboratory controlled by descendants of Henri Beaufour
Ipsen exceeds its targets
Strong growth in sales of Dysport, its botulinum toxin competitor to Botox, generating €594 million in sales

Companies quoted in this study

This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :

Allergan plc

Galderma

Merz Pharmaceuticals

La Roche-Posay

Filorga Cosmétiques (Colgate Palmolive)

Lierac (Laboratoire Native)

Laboratoires Sebbin

Arion

Candela Medical

Deleo

Ipsen

Clinique des Champs Elysées

Choosing this study means :

Access to more than 35 hours of work

Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.

Benefit from 6 years' experience and over 1,500 industry reports already produced

Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.

Our know-how and methodology enable us to produce reports that offer unique value for money.

Access to several thousand articles and paid-for data

Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).

To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)

Guaranteed support after your purchase

A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676

A digital format designed for our users

Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.

Our offers :

the aesthetic medicine market | France

89 €

What are the figures on the size and growth of the market?
What is driving the growth of the market and its evolution?
What is the positioning of companies in the value chain?
Data from several dozen databases

Pack 5 études (-15%) France

75.6 € ^{/ study}

378 € instead of 445 € -15%

5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
Conservez -15% sur les études supplémentaires achetées
Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)

Consultez les conditions du pack et de remboursement des crédits non consommés.